Descriptive data of neutrophil priming activity in transfused units
| CD11b or CD66b up-regulation . | Units received by control patients (N = 532) . | Units received by TRALI patients (N = 321) . |
|---|---|---|
| % cells positive for CD11b, mean ± SD | 9.02 ± 12.7 | 10.8 ± 14.7 |
| % cells positive for CD11b, median (range) | 3.8 (0.0-78.4) | 4.1 (0.0-73.7) |
| % cells positive for CD11b or CD66b, mean ± SD | 5.94 ± 8.4 | 5.12 ± 6.36 |
| % cells positive for CD11b or CD66b, median (range) | 2.4 (0.0-61.9) | 2.8 (0.0-49.9) |
| CD11b or CD66b up-regulation . | Units received by control patients (N = 532) . | Units received by TRALI patients (N = 321) . |
|---|---|---|
| % cells positive for CD11b, mean ± SD | 9.02 ± 12.7 | 10.8 ± 14.7 |
| % cells positive for CD11b, median (range) | 3.8 (0.0-78.4) | 4.1 (0.0-73.7) |
| % cells positive for CD11b or CD66b, mean ± SD | 5.94 ± 8.4 | 5.12 ± 6.36 |
| % cells positive for CD11b or CD66b, median (range) | 2.4 (0.0-61.9) | 2.8 (0.0-49.9) |
In risk factor analysis, total quantities of CD11b up-regulation (% positive cells × plasma volume) in all units received by a patient were a statistically significant risk factor in univariate analysis (Table 9) but not in multivariate analysis.